Compass trials mark a milestone moment for the psychedelics sector

12:35 | Jul 21st

Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale...Show More